Bank of Montreal Can Sells 2,520 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Bank of Montreal Can reduced its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 1.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 243,191 shares of the medical research company’s stock after selling 2,520 shares during the period. Bank of Montreal Can owned 0.13% of IQVIA worth $57,099,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Capital Performance Advisors LLP acquired a new stake in shares of IQVIA in the third quarter valued at about $27,000. Park Place Capital Corp acquired a new stake in shares of IQVIA in the third quarter valued at about $28,000. Versant Capital Management Inc grew its position in shares of IQVIA by 733.3% in the second quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock valued at $26,000 after purchasing an additional 110 shares during the last quarter. Opal Wealth Advisors LLC acquired a new stake in shares of IQVIA in the second quarter valued at about $27,000. Finally, Itau Unibanco Holding S.A. acquired a new stake in shares of IQVIA in the second quarter valued at about $29,000. 89.62% of the stock is currently owned by institutional investors.

IQVIA Stock Up 0.1 %

Shares of IQV opened at $201.44 on Thursday. The company has a market capitalization of $36.56 billion, a P/E ratio of 26.44, a PEG ratio of 2.10 and a beta of 1.51. IQVIA Holdings Inc. has a one year low of $187.62 and a one year high of $261.73. The business’s 50 day simple moving average is $220.36 and its 200-day simple moving average is $226.57. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on IQV. The Goldman Sachs Group lowered their price target on IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. BTIG Research decreased their target price on IQVIA from $290.00 to $260.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Deutsche Bank Aktiengesellschaft decreased their target price on IQVIA from $270.00 to $265.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Truist Financial decreased their target price on IQVIA from $286.00 to $265.00 and set a “buy” rating on the stock in a research report on Monday, November 4th. Finally, Evercore ISI decreased their target price on IQVIA from $270.00 to $265.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. Five investment analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $256.50.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.